 Mersana Therapeutics Inc NASDAQ: MRSN has initiated patient dosing in the UPLIFT study evaluating upifitamab rilsodotin in patients with ovarian cancer. The single-arm registration strategy will evaluate the safety and efficacy of upifitamab rilsodotin in platinum-resistant ovarian cancer patients who have received up to four lines of therapy. 